Jump to Main Contents
国立がん研究センター 中央病院

Home > Information

Information

Sep. 25, 2024
National Cancer Center Hospital on Newsweek’s "World’s Best Specialized Hospitals 2025 (Oncology)"
Sep. 20, 2024
HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Receives Its First Regulatory Approval
Sep. 12, 2024
Investigator-initiated clinical studies to be launched following confirmation of tumor shrinkage induced by the targeted protein degrader E7820 using J-PDX (Japanese cancer patient-derived tissue transplantation models)
Aug. 9, 2024
Start of Fecal Microbiota Transplantation Clinical Study for Esophageal and Gastric Cancer Patients
Jun. 6, 2024
Message from New Director
May 8, 2024
Chugai, NCCH, OMPU and MICIN Start Company-Sponsored Phase I Study in Oncology with a New Decentralized Clinical Trial Structure
Jan. 15, 2024
Result of a Japan-led International Investigator-Initiated Registration-Directed Trial Offers a New Treatment Option of Palbociclib in Combination with Tamoxifen
Jan. 11, 2024
An Asian Multicenter Clinical Trial Evaluating Efficacy of
Computer-Aided Detection for Colonoscopy in Colorectal Cancer Screening
Dec. 1, 2023
Sharing of clinical trial information improves the quality of treatment recommendations by expert panels
Sep. 22, 2023
Introduction video of THE NATIONAL CANCER CENTER HOSPITAL JAPAN has been released
Aug. 29, 2023
Invitation to 8th Annual MASTER KEY Project Online Information Session
Jun. 27, 2023
Memorandum of Cooperation on Decentralized Clinical Trials between the Department of Medical Services and the National Cancer Center Japan.
Apr. 10, 2023
Efficacy of Anti-HER2 Therapy with Trastuzumab Deluxecan in Uterine Carcinosarcoma Consistent with PDX-model predictions of efficacy, paving the way for the development of treatments for rare cancers.
Apr. 3, 2023
A clinical trial of Tazemetostat for pediatric and AYA patients with malignant tumors which have no standard treatment or which is refractory to standard treatment using Patient-Proposed Healthcare Service (NCCH2214/ TURTLE trial) to improve drug access for pediatric and AYA patients with refractory tumors.
Feb. 20, 2023
NCC Announces Positive Top-Line Results of Japan-led international Investigator-Initiated Registration-Directed Phase III Study Evaluating Palbociclib Plus Tamoxifen in Patients with Hormone Receptor-positive, HER2-negative Advanced or Metastatic Breast Cancer (NCCH1607/PATHWAY trial)
Dec. 8, 2022
Asian multicenter prospective study (CHOICE study) to elucidate the pathogenesis of cholangiocarcinoma(including FGFR2-rearranged) launched
Nov. 2, 2022
Yusuke Okuma has been awarded “Best of the AACR Journals”
Oct. 20, 2022
National Cancer Center Hospital on Newsweek’s “World’s Best Specialized Hospitals 2023 (Oncology)”
Aug. 24, 2022
Large scale clinical trial for Neuroendocrine Carcinoma (NEC), a rare and refractory cancer establishes current chemotherapy for advanced and recurrent cancer as standard therapy
Aug. 5, 2022
Prospective Cohort Study demonstrates ESD as primary choice of treatment for neoplasia of over 2cm
Aug. 1, 2022
Supporting Cancer Registration in Viet Nam
Jul. 1, 2022
Utility of gene panel testing for comprehensive genomic profiling of blood cancers demonstrated
May 25, 2022
Cooperation with the U.S. National Cancer Institute welcomed by Japan-US leaders in joint statement- role of National Cancer Center highlighted
Mar. 18, 2022
Aberrant activation of cell cycle-related kinases in uterine leiomyosarcoma
Feb. 1, 2022
Virtual Meeting with Tata Memorial Centre of India, Celebrating the Conclusion of Memorandum of Understanding
Jan. 28, 2022
Virtual Meeting with Gansu Provincial Cancer Hospital in China
Dec. 23, 2021
Launch of an Asian international collaborative prospective study on 6 advanced cancers common in Asia
Dec. 14, 2021
Endoscopists at the National Cancer Center Hospital selected as world-class experts in endoscopic mucosal resection (EMR) by Expertscape
Oct. 20, 2021
MASTER KEY ASIA
Oct. 7, 2021
National Cancer Center Hospital on Newsweek’s “World’s Best Specialized Hospitals 2022 (Oncology)”
Sep. 13, 2021
Webinar on Clinical Research with Guangxi, China
Sep. 8, 2021
Shun-ichi Watanabe awarded the Ginsberg Lectureship Award for Surgery at the 2021 World Conference on Lung Cancer
Jun. 2, 2021
SARS-CoV-2 antibody status in patients with cancer during the COVID-19 pandemic in Japan
May 14, 2021
NATIONAL CANCER CENTER AND EISAI COMMENCE JOINT RESEARCH AND DEVELOPMENT PROJECT “BASIC RESEARCH ON THE DRUG DISCOVERY AND DEVELOPMENT TO ACCELERATE DEVELOPMENT OF ANTICANCER DRUGS IN TREATMENT OF PATIENTS WITH RARE CANCERS AND REFRACTORY CANCERS”, USING PDX WITH HIGH PREDICTABILITY OF CLINICAL OUTCOMES, AND CANCER GENOME DATA
Mar. 23, 2021
First drug approved for unresectable thymic carcinoma
Feb. 5, 2021
Endoscopy Lectures on the web
Nov. 19, 2020
MOU signed with Clinical Research Malaysia (CRM)
Oct. 19, 2020
National Cancer Center Hospital on Newsweek’s “World’s Best Specialized Hospitals 2021 (Oncology)”
Sep. 17, 2020
The Endoscopy Center Sharing Expertise Overseas
Sep. 9, 2020
Asian early phase drug development network
ATLAS Project – Paving the way towards developing drugs with Asian partners
Aug. 20, 2020
NCC joins GSK’s oncology development network
Mar. 2, 2020
HE Professor Tomasz Grodzki, Polish Senate Marshal visit
Feb. 21, 2020
To contain the spread of new coronavirus, the National Cancer Center of Japan requests your kind cooperation for the welfare of our patients
Jan. 29, 2020
Clinical Trial Investigators visit NCC Hospital
Dec. 11, 2019
Test Result of New Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting Proves Higher Efficacy Than Standard Antiemetic Therapy
Nov. 7, 2019
Commencement of Clinical Trial of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma and Angiosarcoma
Oct. 10, 2019
NCC colorectal Surgeons visit Sakha Republic, Russia
May 29, 2019
Cancer Gene Panel Test OncoGuideTM NCC Oncopanel System added to Health Insurance Coverage list
Mar. 7, 2019
Kazakhstan Delegation visit
Jan. 22, 2019
Dr Kazuaki Shimada appointed Honorary Professor at Tianjin Medical University Cancer Institute and Hospital
Nov. 19, 2018
Action across borders
Nov. 12, 2018
Facilitating International Clinical Trials Initiated by
Japanese Academic Institutions
Japan-led Global Investigator-Initiated Registration-Directed Trial of Advanced or Metastatic Breast Cancer (PATHWAY trial) Has Started
Apr. 3, 2018
National Cancer Center Hospital offers Next Generation Sequencing tests as ‘Advanced Medical Care’
Towards coverage under national health insurance system
Apr. 3, 2018
Advanced Medical Care Approval Received for Multiplex Gene Panel Testing
to Advancing Personalized Medicine
Feb. 5, 2018
Maestro Chung Visit
Aug. 1, 2017
On-Table Adaptive Radiation Therapy
Jul. 31, 2017
The MASTER KEY PROJECT
Genomic medicine in Rare Cancers:
A collaboration between the industry and academia